Arcus Biosciences to Participate in Multiple Upcoming Investor Conferences
23 August 2023 - 3:00PM
Business Wire
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global
biopharmaceutical company focused on developing differentiated
molecules and combination therapies for people with cancer,
announced that its management team will participate in the
following upcoming investor conferences in September:
2023 Wells Fargo Healthcare Conference
Date: Wednesday, September 6th, 2023 at 10:15 a.m. ET Location:
Boston, MA Format: Fireside Chat
Citi 18th Annual BioPharma Conference
Date: Wednesday, September 6th, 2023 at 3:30 p.m. ET Location:
Boston, MA Format: Company Panel — Immuno-Oncology
Morgan Stanley 21st Annual Global
Healthcare Conference Date: Tuesday, September 12th, 2023 at
4:15 p.m. ET Location: New York, NY Format: Fireside Chat
2023 Cantor Fitzgerald Global Healthcare
Conference Date: Tuesday, September 26th, 2023 at 10:20 a.m. ET
Location: New York, NY Format: Fireside Chat
Live webcasts of the fireside chats and panel will be available
by visiting the “Investors & Media” section of the Arcus
Biosciences website at www.arcusbio.com. Replays will be available
following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical
company developing differentiated molecules and combination
medicines for people with cancer. In partnership with industry
partners, patients and physicians around the world, Arcus is
expediting the development of first- or best-in-class medicines
against well-characterized biological targets and pathways and
studying novel, biology-driven combinations that have the potential
to help people with cancer live longer. Founded in 2015, the
company has expedited the development of multiple investigational
medicines into clinical studies, including new combination
approaches that target TIGIT, PD-1, the adenosine axis (CD73 and
dual A2a/A2b receptor) and HIF-2a. For more information about Arcus
Biosciences’ clinical and pre-clinical programs, please visit
www.arcusbio.com or follow us on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230823679974/en/
Media Inquiries Holli Kolkey VP of Corporate
Communications (650) 922-1269 hkolkey@arcusbio.com
Investor Inquiries Pia Eaves (Banerjee) Head of Investor
Relations & Strategy (617) 459-2006 peaves@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024